WARNING: Don’t Take Boniva or Fosamax

by | Apr 12, 2010


A green chalkboard with the message 'I LOVE YOU' written in white chalk.As cute as Sally Field is, she is not a doctor, she doesn’t even play one on TV. She’s just an actress who is getting paid to advertise a drug. I wonder if she is worried about all of the side-effects. Now it appears that her radio and TV ads for Boniva, which is similar to Fosamax, may need to add a new WARNING: “Tell your doctor if your femur snaps in half while you’re just standing in the kitchen doing nothing.”


This of course would have to be added to the already worrisome list of side-effects that are recited so fast that you can’t really comprehend them anyway.


The other previously known side-effects include the following: “Don’t take Boniva if you have low blood calcium, severe kidney disease, or you can’t sit or stand for at least one hour.” (because it could wear a hole in your stomach, or cause cancer of your esophagus).


“Stop taking Boniva and tell your doctor if you have difficult or painful swallowing, chest pain, or severe or continuing heartburn, as these may be signs of serious upper digestive problems.” (like an ulcer or Osteonecrosis of the Jaw, which is the disintegration of bone in your jaw)

“If severe bone, joint and/or muscle pain develops tell your doctor.” (this could be a sign that the drug you’ve been taking for five years or more has actually stopped your bones from remodeling as they should every year and now you’ve got new bone on top of the old brittle bone that has become so heavy that it’s now about to snap in two and perhaps cause more severe problems sooner than would have resulted had you never taken the drug at all)


Watch the Boniva ad with Sally Field on the player below. Remember the age old saying, “If it sounds too good to be true, it probably is.”


The truth is that diet and exercise along with balancing your hormones is the only way to truly prevent and reverse Osteoporosis.


To learn more about the best way to prevent, test and treat Osteoporosis naturally, click here.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

2 + 11 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });